Schreiner MediPharm’s Flexi-Cap Plus incorporates a label-integrated tear strip for enhanced security.
Image courtesy of Schreiner MediPharm
Illegal reuse of empty medicine containers with original labels is a problem, because used, original containers can be filled with ineffective or harmful counterfeit substances. The alleged originals are subsequently put on the market without revealing any signs of tampering at first glance. To counteract these illegal practices, Schreiner MediPharm’s Flexi-Cap combines a film cap with a label for clear and irreversible first-opening indication. The next-generation Flexi-Cap Plus features a tear strip running through the label as an integrated element, rather than through the film cap, to protect against tampering. The label is destroyed upon initial opening and can no longer be reused as an alleged original, because end-users can see that the container has been opened.
By adding other overt and covert security technologies, such as holograms, color-shifting inks, void effects, or security pigments, further hurdles to tampering can be raised. Flexi-Cap Plus can be flexibly customized to accommodate various glass container types, shapes, and sizes. Particularly useful for small containers, the lid of the film cap also offers additional space that can be used for imprinting barcodes or integrating near-field communication chips for interactive applications. The label construction is applied without heat and thus suitable for temperature-sensitive medicines.
Source: Schreiner MediPharm
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.